AU742818B2 - Novel polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes - Google Patents

Novel polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes Download PDF

Info

Publication number
AU742818B2
AU742818B2 AU51239/98A AU5123998A AU742818B2 AU 742818 B2 AU742818 B2 AU 742818B2 AU 51239/98 A AU51239/98 A AU 51239/98A AU 5123998 A AU5123998 A AU 5123998A AU 742818 B2 AU742818 B2 AU 742818B2
Authority
AU
Australia
Prior art keywords
residues
free
complex
complex according
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU51239/98A
Other languages
English (en)
Other versions
AU5123998A (en
Inventor
Patrick Midoux
Michel Monsigny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDM Immuno Designed Molecules
Original Assignee
IDM Immuno Designed Molecules
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IDM Immuno Designed Molecules filed Critical IDM Immuno Designed Molecules
Publication of AU5123998A publication Critical patent/AU5123998A/en
Application granted granted Critical
Publication of AU742818B2 publication Critical patent/AU742818B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AU51239/98A 1996-11-15 1997-11-10 Novel polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes Ceased AU742818B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/13990 1996-11-15
FR9613990A FR2755976B1 (fr) 1996-11-15 1996-11-15 Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
PCT/FR1997/002022 WO1998022610A1 (fr) 1996-11-15 1997-11-10 Nouveaux complexes polymeriques pour la transfection d'acides nucleiques, avec des residus destabilisant des membranes cellulaires

Publications (2)

Publication Number Publication Date
AU5123998A AU5123998A (en) 1998-06-10
AU742818B2 true AU742818B2 (en) 2002-01-10

Family

ID=9497684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51239/98A Ceased AU742818B2 (en) 1996-11-15 1997-11-10 Novel polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes

Country Status (11)

Country Link
US (1) US6372499B1 (enExample)
EP (1) EP0946744B1 (enExample)
JP (1) JP2001504344A (enExample)
AT (1) ATE274066T1 (enExample)
AU (1) AU742818B2 (enExample)
CA (1) CA2267833A1 (enExample)
DE (1) DE69730348T2 (enExample)
ES (1) ES2225992T3 (enExample)
FR (1) FR2755976B1 (enExample)
IL (1) IL128912A (enExample)
WO (1) WO1998022610A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
ES2213397T3 (es) * 1998-12-02 2004-08-16 I.D.M. Immuno-Designed Molecules Nuevos conjugados oligomericos capaces de transferir moleculas biologicas a las celulas.
WO2001016295A1 (en) * 1999-09-01 2001-03-08 The Regents Of The University Of California Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
CA2394758A1 (en) * 1999-12-29 2001-07-05 A. James Mixson Histidine-containing copolymers enhance pharmaceutical agent delivery
DK1301213T3 (en) * 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
FR2812658B1 (fr) * 2000-08-01 2005-04-15 De Bruno Vandiere Procede d'analyse d'acides nucleiques
US7465708B2 (en) 2002-11-25 2008-12-16 Mixson A James Branched cationic copolymers and methods for antimicrobial use
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060040879A1 (en) * 2004-08-21 2006-02-23 Kosak Kenneth M Chloroquine coupled nucleic acids and methods for their synthesis
AU2005284727A1 (en) * 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
AU2006306228A1 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US8389485B2 (en) * 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9162191B2 (en) * 2012-11-15 2015-10-20 Board Of Trustees Of The University Of Alabama Imidazole-containing polymer membranes and methods of use
CN102949729B (zh) * 2012-11-20 2014-06-18 中国科学院宁波材料技术与工程研究所 主动靶向型小干扰核糖核酸输送载体及其制备方法
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
AR122446A1 (es) * 2020-04-29 2022-09-14 Medimmune Llc Composiciones y métodos para suministrar agentes farmacéuticamente activos
WO2022189361A1 (en) * 2021-03-08 2022-09-15 Universiteit Gent Conjugates including multiple saccharidic chains on a linear protein and uses in mammals feed

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
ES2090049T3 (es) * 1989-03-16 1996-10-16 Boehringer Ingelheim Int Unidades geneticas para la inhibicion de la funcion de arn.
CA2097589C (en) * 1990-12-19 1998-05-05 Lee Josephson Targeting of therapeutic agents using polysaccharides
DE4104186A1 (de) * 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
WO1993009176A2 (en) * 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
AU682308C (en) * 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
US5733762A (en) * 1994-04-28 1998-03-31 I.D.M. Immuno-Designed Molecules Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEZO G.ET AL. BIOPOLYMERS 33 (6):873-875 (1993) *

Also Published As

Publication number Publication date
AU5123998A (en) 1998-06-10
EP0946744A1 (fr) 1999-10-06
ATE274066T1 (de) 2004-09-15
US6372499B1 (en) 2002-04-16
IL128912A (en) 2006-06-11
DE69730348T2 (de) 2005-09-01
ES2225992T3 (es) 2005-03-16
IL128912A0 (en) 2000-02-17
WO1998022610A1 (fr) 1998-05-28
JP2001504344A (ja) 2001-04-03
FR2755976B1 (fr) 1999-01-15
DE69730348D1 (de) 2004-09-23
FR2755976A1 (fr) 1998-05-22
EP0946744B1 (fr) 2004-08-18
CA2267833A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
US6372499B1 (en) Polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes
AU681735B2 (en) Self-assembling polynucleotide delivery system comprising dendrimer polycations
AU695056B2 (en) Novel nucleic acid/polymer complexes, method for preparing same and use thereof for cell transfection
US6113946A (en) Self-assembling polynucleotide delivery system comprising dendrimer polycations
Erbacher et al. Glycosylated polylysine/DNA complexes: gene transfer efficiency in relation with the size and the sugar substitution level of glycosylated polylysines and with the plasmid size
Midoux et al. Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes
US7001891B1 (en) Biodegradable polycation composition for delivery of an anionic macromolecule
KR20010071279A (ko) 간세포를 표적으로하는 폴리에틸렌 글리콜-접합된폴리-ｌ-리신 고분자로된 유전자 운반체
US20020146826A1 (en) Cationic polysaccharide compositions
US9744247B2 (en) Functionalized liposomes useful for the delivery of bioactive compounds
JPH10504709A (ja) ポリヌクレオチドの細胞への標的を定めた送達を増大させるための細菌成分の利用
EP1098632A1 (en) Charge reversal of polyion complexes
WO2008115799A1 (en) Novel gene delivery vectors for human mesenchymal stem cells
US20230121879A1 (en) Methods for preparing nanoparticle compositions containing histidine-lysine copolymers
Fajac et al. Gene therapy of cystic fibrosis: the glycofection approach
CN117752810A (zh) 一种基于CD16a的靶向脂质纳米粒及其组合物、药物制剂及应用
EP1248838A1 (en) Polyampholytes for delivering polyions to a cell
KR100346577B1 (ko) 간세포 특이적인 담체 및 이의 ｄｎａ와의 복합체
White Novel Bioconjugate Strategies to Improve Nonviral Gene Deliver to Liver: Systematic Optimization of Multi-Component Delivery Vehicles
Lamka et al. Distribution of catalase, ribonuclease and superoxide dismutase modified by monomethoxy (polyethylene glycol) into rat central lymph and lymphatic modes
Midoux et al. Glycofectins: Synthetic Vectors for a Sugar Specific Gene Targeting
Akita et al. Pharmacokinetics of gene delivery in cells
Erbacher et al. Specific Gene Transfer Based on Biotinylated and Gluconoylated Polylysine/Plasmid Complexes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)